Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HANSOH PHARMA Opens Up ~4%; Upfront Payment USD80M Received After Granting Product License to Regeneron
Recommend 2 Positive 5 Negative 1 |
||||
|
||||
|
Blue-chip pharma stock HANSOH PHARMA (03692.HK) opened 3.85% higher today (3rd). It last traded at HKD27, up 3.85%, on a pre-market volume of 70,700 shares, involving HKD1.9083 million. The group announced after market close yesterday (2nd) that it has granted Regeneron (REGN.US) an exclusive worldwide license (excluding Mainland China, Hong Kong, and Macau) for its investigational dual GLP-1/GIP receptor agonist. HANSOH PHARMA will receive an upfront payment of USD80 million and be eligible to receive up to USD1.93 billion in milestone payments, as well as double-digit royalties on potential future product sales. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
